Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients-Reference-Cited by-同舟云学术

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients

Published:2015-04-27 Issue:6 Volume:45 Page:576-583
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Akaza Hideyuki,Naito Seiji,Ueno Naomi,Aoki Kouji,Houzawa Hiroyuki,Pitman Lowenthal Susan,Lee Sang-Yoon

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/45/6/576/14097080/hyv045.pdf

Reference25 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

3. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety;Uemura;Jpn J Clin Oncol,2010

4. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma;Tomita;Jpn J Clin Oncol,2010

5. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib;Rini;J Natl Cancer Inst,2011

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study;Clinical and Translational Oncology;2024-04-05

2. Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications;European Journal of Clinical Pharmacology;2024-03-14

3. Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study;International Journal of Cardiology;2023-06

4. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05

5. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma;Biomedicines;2023-01-11